je.st
news
Athersys, Inc. (ATHX) Upgraded to Buy at Zacks Investment Research
2016-03-12 01:37:03| Biotech - Topix.net
The brokerage presently has a $2.50 price target on the biopharmaceutical company's stock. Zacks Investment Research 's price objective would indicate a potential upside of 14.68% from the company's current price.
Tags: buy
research
investment
upgraded
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||